KLRA Stock Analysis: Kailera Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.849m USD | 12M Return: -14.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.3M
Warnings
Tailwinds
Seasonality 0.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kailera Therapeutics (NASDAQ: KLRA) is a U.S.-based, clinical-stage biopharmaceutical company founded in 2024 and headquartered in Waltham, Massachusetts. The company focuses on developing injectable peptides, oral peptides, and oral small molecules for obesity and related metabolic conditions. It holds exclusive global development and commercialization rights (outside Greater China) to four metabolic disease assets.
Its lead programs include KAI-9531, an injectable GLP-1/GIP dual agonist; KAI-4729, an injectable GLP-1/GIP/glucagon tri-agonist; and KAI-7535, an oral small molecule GLP-1 receptor agonist. As a clinical-stage biotech, Kailera does not yet generate product revenue and is dependent on capital markets and pipeline advancement. The company is positioned within the broader obesity therapeutics segment, which has been driven by growing demand for GLP-1-based treatments. KLRA trades as a mid-cap stock following its April 2026 IPO.
- KAI-9531 injectable Phase 2 obesity data readout
- GLP-1 market competition intensifies from Lilly and Novo Nordisk
- Cash burn rises as pipeline advances toward Phase 3 trials
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.20 > 0.02 and ΔFCF/TA -19.58 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.19 > 3% & CFO -120.2m > Net Income -149.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.67 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (117.9m) vs prev 0.0% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.76 (Total Current Assets 530.3m - Total Current Liabilities 54.8m) / Total Assets 624.8m |
| B: -0.72 (Retained Earnings -447.5m / Total Assets 624.8m) |
| C: -0.39 (EBIT TTM -158.3m / Avg Total Assets 401.6m) |
| D: -0.41 (Book Value of Equity -432.1m / Total Liabilities 1.06b) |
| Altman-Z'' = -0.42 = B |
As of July 08, 2026, the stock is trading at USD 22.24 with a total of 1,648,150 shares traded. Over the past week, the price has changed by +2.63%, over one month by +12.89%, over three months by -14.46% and over the past year by -14.46%.
Current recommended Stop Loss: 17.60 (which is 20.9% or 2.8 ATR below the current price).
Kailera Therapeutics has no consensus analysts rating.
Revenue TTM = 0.0 USD
EBIT TTM = -158.3m USD
EBITDA TTM = -158.0m USD
Long Term Debt = 9.44m USD (estimated: total debt 10.5m - short term 1.03m)
Short Term Debt = 1.03m USD (from shortTermDebt, last quarter)
Debt = 10.5m USD (from shortLongTermDebtTotal, last quarter) (leases 10.5m already included)
Net Debt = -508.7m USD (calculated: Debt 10.5m - CCE 519.2m)
Enterprise Value = 2.34b USD (2.85b + Debt 10.5m - CCE 519.2m)
Interest Coverage Ratio = unknown (Ebit TTM -158.3m / Interest Expense TTM 0.0)
EV/FCF = -19.14x (Enterprise Value 2.34b / FCF TTM -122.3m)
FCF Yield = -5.23% (FCF TTM -122.3m / Enterprise Value 2.34b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 3.75 (Enterprise Value 2.34b / Total Assets 624.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 10.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -125.1m (EBIT -158.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.56 (Total Current Assets 530.3m / Total Current Liabilities 61.9m)
Debt / Equity = -0.02 (negative equity) (Debt 10.5m / totalStockholderEquity, last quarter -432.1m)
Debt / EBITDA = 3.22 (negative EBITDA) (Net Debt -508.7m / EBITDA -158.0m)
Debt / FCF = 4.16 (negative FCF - burning cash) (Net Debt -508.7m / FCF TTM -122.3m)
Total Stockholder Equity = -356.5m (last fiscal year from totalStockholderEquity)
RoA = -37.09% (Net Income -149.0m / Total Assets 624.8m)
RoE = 41.79% (negative equity) (Net Income TTM -149.0m / Total Stockholder Equity -356.5m)
RoCE = 45.63% (negative capital employed) (EBIT -158.3m / Capital Employed (Equity -356.5m + L.T.Debt 9.44m))
RoIC = -21.91% (negative operating profit) (NOPAT -125.1m / Invested Capital 570.9m)
WACC = 10.37% (E(2.85b)/V(2.86b) * Re(10.41%) + D(10.5m)/V(2.86b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.41% (= CAPM, Blume Beta Adj.)
[DCF] Fair Price = unknown (Cash Flow -122.3m)
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.72 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.89 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=-4.29 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+0.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.73 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+13.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +0% (up=0, down=0)